Benralizumab is a humanized monoclonal antibody that targets the interleukin-5 receptor alpha subunit (IL-5Rα) found on eosinophils and basophils, which are types of white blood cells involved in inflammation. By binding to IL-5Rα, benralizumab attracts natural killer (NK) cells, which then destroy eosinophils and basophils through a process called antibody-dependent cell-mediated cytotoxicity (ADCC).

Eosinophils play a significant role in the inflammation seen in certain diseases, such as severe asthma with an eosinophilic phenotype and EGPA. By reducing the number of eosinophils in the blood and tissues, benralizumab helps decrease inflammation and the symptoms associated with these conditions. The medication does not provide immediate relief for acute symptoms but works over time to reduce exacerbations and the need for oral corticosteroids.

benralizumab

Common brand names

Approved use in